Please login
NASCOLA News - Bulletin Item
  

Posted: Friday, November 20, 2009

NASCOLA members publish in American Journal of Clinical Pathology: Laboratory assessment of factor VIII inhibitor titer: the North American Specialized Coagulation Laboratory Association experience.

 

NASCOLA members, Ellinor Peerschke, Donna Castellone, Marlies Ledford-Kraemer, and Elizabeth Van Cott, along with Piet Meijer from ECAT, have published an analysis of factor VIII inhibitors as assessed by NASCOLA proficiency testing.  The abstract is below, along with a link to the full article for NASCOLA members who are subscribers to Am J Clin Pathol:

 

Laboratory assessment of factor VIII inhibitor titer: the North American Specialized Coagulation Laboratory Association experience.

Quantification of inhibitory antibodies against infused factor VIII (FVIII) has an important role in the management of patients with hemophilia A. This article summarizes results from the largest North American FVIII inhibitor proficiency testing challenge conducted to date. Test samples, 4 negative and 4 positive (1-3 Bethesda units [BU]/mL), were distributed by the ECAT Foundation in conjunction with the North American Specialized Coagulation Laboratory Association and analyzed by 38 to 42 laboratories in 2006 and 2007. Whereas laboratories were able to distinguish between the absence and presence of low-titer FVIII inhibitors, the intralaboratory coefficient of variation was high (30%-42%) for inhibitor-positive samples, and the definition of lower detection limits of the assay was variable (0-1 BU/mL). Most laboratories performed the Bethesda assay with commercially supplied buffered normal pooled plasma in a 1:1 mix with patient plasma. These data provide information for the development of consensus guidelines to improve FVIII inhibitor quantification.


Am J Clin Pathol. 2009 Apr;131(4):552-8.


The link to the full text for subscribers